Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
Authors
Keywords
Gemcitabine, Complete Pathologic Response, Chemotherapeutic Regimen, Resectable Disease, Histopathologic Response
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 21, Issue 13, Pages 4351-4358
Publisher
Springer Nature
Online
2014-08-05
DOI
10.1245/s10434-014-3842-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer
- (2013) Yousuke Nakai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy
- (2013) Koichiro Tsutsumi et al. PANCREATOLOGY
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
- (2013) Ching-Wei D. Tzeng et al. HPB
- Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas – A retrospective tumor marker prognostic study
- (2013) Marius Distler et al. International Journal of Surgery
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
- (2012) Werner Hartwig et al. ANNALS OF SURGICAL ONCOLOGY
- Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy
- (2012) Todd M. Bauer et al. CANCER
- Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
- (2012) Matthew H. G. Katz et al. CANCER
- EMT and Dissemination Precede Pancreatic Tumor Formation
- (2012) Andrew D. Rhim et al. CELL
- Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
- (2012) Jordan M. Winter et al. JOURNAL OF SURGICAL ONCOLOGY
- Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma
- (2011) Deyali Chatterjee et al. CANCER
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
- (2010) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
- (2010) Nazik HAMMAD et al. Asia-Pacific Journal of Clinical Oncology
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
- Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma
- (2010) Philip Bao et al. HPB
- CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
- (2009) Daniele Marrelli et al. AMERICAN JOURNAL OF SURGERY
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?
- (2009) O. Turrini et al. JOURNAL OF GASTROINTESTINAL SURGERY
- CA 19-9 Response as an Early Indicator of the Effectiveness of Gemcitabine in Patients with Advanced Pancreatic Cancer
- (2008) Yousuke Nakai et al. ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now